Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Issues of Adherence in Treating Individuals With Schizophrenia

neuroscienceCME Multimedia Snack

Premiere Date: Wednesday, December 12, 2012

This activity offers CE credit for:

1. Physicians (CME)
2. Pharmacists (ACPE)
3. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Thursday, December 12, 2013
Note: Credit Is No Longer Available

Faculty

S. Charles Schulz, MD (Moderator) Professor and Head Donald W. Hastings Endowed Chair Department of Psychiatry University of Minnesota Medical School Minneapolis, MN

John Lauriello, MD  Chancellors Chair of Excellence - Professor and Chairman Department of Psychiatry University of Missouri School of Medicine Columbia, MO

Statement of Need

According to clinical guidelines, antipsychotic medication represents the treatment of choice in psychosis. Nevertheless, studies show that half to almost three-quarters of all patients discontinue their antipsychotic medication after three months. This lack of adherence can be ascribed to many factors, including medication side effects and poor illness insight, as well as system barriers such as inconsistent aftercare coordination.(1)

A number of pharmacological strategies can facilitate adherence. Many clinicians only consider long-acting medication after the patient has repeatedly demonstrated poor adherence to treatment, with consequent relapse or illness exacerbation. Unfortunately, a tremendous amount of time for treatment has been lost by that point, and clinicians should be much more proactive in trying to avoid any and all relapses.(2)

This neuroscienceCME Snack offers clinicians various unique insights into antipsychotic medication adherence and offers practical approaches to improve patient–clinician dialogue and strategies to manage adherence in a community setting.

---

1. Moritz S, Favrod J, Andreou C, et al. Beyond the usual suspects: positive attitudes towards positive symptoms is associated with medication noncompliance in psychosis. Schizophr Bull. February 15, 2012. [Epub ahead of print].
2. Kane JM. Management strategies for the treatment of schizophrenia. J Clin Psychiatry. 1999;60(Suppl 12):13-17. PMID: 10372604.

Activity Goal

The goal of this activity is to present the various barriers to adherence to antipsychotic medication and to offer strategies to improve adherence and outcomes in patient care in schizophrenia.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Develop a strategy that considers system, provider, and patient–caregiver barriers to medication adherence and integrates best practices, including family involvement, pharmacotherapy, and psychoeducation as part of an individualized, multimodal, long-term treatment strategy for persons with schizophrenia.

Financial Support

This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Target Audience

Physicians, pharmacists, and other health care professionals who work with individuals with schizophrenia.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.05 CEUs)
Universal Activity Number: 0376-0000-12-034-H01-P (recorded programs)
Activity Type: knowledge-based

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST735 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Schulz has disclosed that he received grant support from AstraZeneca Pharmaceutical LP; Otsuka America Pharmaceutical, Inc.; and Myriad Genetics Inc./Rules-Based Medicine, Inc. He serves as a consultant for Lilly USA, LLC..

Dr. Lauriello has disclosed that he receives grants/research support from Sunovion Pharmaceuticals, Inc. He serves as a consultant to Otsuka America Pharmaceutical, Inc. and Ortho-McNeil Pharmaceuticals, Inc.

Tony Graham, MD (peer review) has no disclosures to report.

Robert Kennedy (planning committee) has no disclosures to report.

Joy Bartnett Leffler, MLA, NASW, CSE (planning committee) has no disclosures to report.

Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.

Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.

Unlabeled Use Disclosure

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

CME Outfitters, LLC, the faculty, and Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).